Pirbright Institute creates swine flu antibodies
This indicates they could be used to develop and assess human antibody therapies and their delivery methods.
The pig antibodies also have the potential to improve how flu virus evolution is monitored and inform decisions about annual flu vaccine selection.
Antibodies form a vital part of the immune system’s response and help to fight off infections by latching on to important parts of invading microorganisms to neutralise them.
In the case of flu viruses, many antibodies target a protein on the surface of the virus called haemagglutinin, which then prevents the virus from entering cells and replicating.
Pirbright scientists worked in collaboration with the University of Oxford, The Francis Crick Institute and The Pirbright Livestock Antibody Hub to generate pig antibodies in the laboratory (known as monoclonal antibodies, or mAbs). These are the first pig mAbs to be generated which target the influenza virus.
These mAbs recognise the same two main sites of the flu virus haemagglutinin protein that are targeted by human antibodies, and were found to be just as effective at neutralising the swine flu strain that caused the 2009 pandemic.
Pigs that were treated with one of the mAbs prior to infection were protected from severe disease and the flu virus was eliminated from their lungs. This indicates that the mAbs have great therapeutic potential and could be used to evaluate mAb delivery methods.
Ferrets are commonly used as models to monitor flu virus evolution and to design or select vaccines that will provide the best protection against human seasonal flu strains. However, ferret antibodies only recognise one of the two main haemagglutinin sites that human antibodies target. The findings in the study, published in PLOS Pathogens, demonstrate that pig mAbs are more closely matched to human antibodies and could therefore improve the reliability of human vaccine selection. ■